Biospyder Technologies, Inc.

Biospyder Technologies, Inc., doing business as Biospyder, is a small-business manufacturer of targeted RNA sequencing and gene expression profiling services that operates almost exclusively as a prime contractor (94% of awards) to federal research agencies, principally the Environmental Protection Agency. The company is based in Elk Grove, California, with laboratory facilities in Carlsbad, California and Research Triangle Park, North Carolina, and competes predominantly full-and-open rather than under socioeconomic set-asides, though two recent IDIQ awards carry Total Small Business designations.

Biospyder's core capability is high-throughput transcriptomics analysis delivered through two proprietary technology platforms. The Tempo-Seq platform performs targeted RNA sequencing and gene expression profiling on cell lysates, tissue samples, whole body homogenates, and purified RNA at analysis depths ranging from 1 to 30 million mapped reads per sample. The emerging Tempo-LINC single-cell technology enables high-sensitivity single-cell gene expression profiling at scale across tens of thousands of cells with instrument-free workflows amenable to automation. Representative prime contracts include a $1.159 billion EPA delivery order (IDIQ 68HERC20D0028, internal tracking TO 26) for Tempo-Seq analysis of 24,948 samples supporting high-throughput transcriptomics research; a $766.234 million delivery order (TO 42) for sequencing 15,492 cell lysate samples; and a $617.123 million delivery order (internal TO 34) for cell-lysate analysis supporting EPA's Center for Computational Toxicology and Exposure and National Center for Computational Toxicology research programs.

The Environmental Protection Agency dominates Biospyder's customer footprint, representing 90% of awards by count and 99% of combined potential value. EPA's Office of Research and Development alone holds 142 awards valued at $64.7 million, with EPA's Office of Chemical Safety and Pollution Prevention holding an additional $25.5 million across 2 awards. The Department of Health and Human Services National Institutes of Health (15 awards), the Department of Veterans Affairs Veterans Integrated Service Network 22 (5 awards, $197 thousand potential value), and the Department of the Army Corps of Engineers Engineer Research and Development Center (1 award, $1.6 million) are secondary customers. NIGMS awarded a Phase II SBIR grant to Biospyder in June 2023 for development of Tempo-LINC high-throughput single-cell gene expression profiling, with ultimate completion in May 2025.

Biospyder holds multiple EPA IDIQs anchoring its delivery-order volume. The largest is a $25 million single-award IDIQ (68HERC25D0026, awarded September 2025 by EPA's Office of Chemical Safety and Pollution Prevention) set aside for total small business with performance through September 2030; 1 task order valued at $495.5 thousand has issued against it as of the source date. An older IDIQ (68HERC20D0028, Office of Research and Development) carries 60 task orders with $11.5 million combined potential value. A $9.5 million EPA IDIQ for targeted RNA sequencing appears in multiple delivery-order award summaries. Biospyder also places work under EPA Blanket Purchase Agreement EPBPA16D0003 (58 task orders, $7.1 million combined potential value) and holds a $150.8 thousand IDIQ with the Department of Veterans Affairs. Across the award portfolio, research and development in the physical, engineering, and life sciences dominates the NAICS distribution (156 awards), with secondary concentration in biotechnology R&D (25 awards).

Activity has remained steady over the past five years (13 to 16 awards annually in 2022–2024, declining to 12 in 2025 and 4 in the first five months of 2026) with combined potential value across all 190 awards of $94.5 million and $51.3 million obligated (54% realization). Only two awards face completion in the next twenty-four months, carrying combined potential value of $240 thousand, indicating minimal near-term recompete exposure.

SCI-reported invoiced revenue on federal service contracts above the $150,000 threshold totaled $6.3 million across FY2022–FY2025 (FY2023: $3.6 million; FY2024: $1.9 million; FY2025: $766 thousand), with median government-paid rates around $1,697.31 per hour and senior labor pricing through $1,783.02 per hour on prime contracts. Biospyder performs work directly rather than through subcontractors on its SCI-reportable contracts, with zero average sub-hours share. The company also subcontracts to Battelle Memorial Institute on National Institute of Environmental Health Sciences and National Toxicology Program work, providing Tempo-Seq kits and human, rat, and mouse surrogate S1500+ assay services across multiple awards dating from July 2022 through May 2026. Under a Jackson Laboratory grant sub-award (March 2023), Biospyder is developing spatial-transcriptomic adaptations of Tempo-LINC through collaboration with AtlasXomics and spatial-barcoding partners.